Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia

Fahrettin Covut, Divya Gupta, Raisa Pinto, Nina Dambrosio, Najla El Jurdi, Howard Meyerson, Masumi Ueda, Merle Kolk, Richard Creger, Leland Metheny, Brenda W. Cooper, Paolo F. Caimi, Ehsan Malek, Folashade Otegbeye, Hillard M. Lazarus, Marcos De Lima, Benjamin K. Tomlinson

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Early identification of acute myeloid leukemia patients with persistent disease after cytarabine and an anthracycline (7+3) induction is crucial to improve outcome. In the present retrospective study we analyzed the previously described methods to predict outcome of induction. Rapid clearance of peripheral blasts and day 14 bone marrow biopsy provided additional prognostic value over existing prognostic factors.

Original languageEnglish (US)
Pages (from-to)73-82
Number of pages10
JournalClinical Lymphoma, Myeloma and Leukemia
Volume19
Issue number2
DOIs
StatePublished - Feb 2019
Externally publishedYes

Keywords

  • AML
  • Complete remission
  • Day 14 bone marrow
  • Peripheral blast disappearance
  • Prognosis

PubMed: MeSH publication types

  • Journal Article
  • Research Support, Non-U.S. Gov't

Fingerprint Dive into the research topics of 'Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia'. Together they form a unique fingerprint.

Cite this